Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 at the 2022 Metals in Medicine Gordon Research Conference.Read more
Bold Therapeutics is pleased to have been invited to present at Bio Korea 2022 as part of the Canadian trade delegation.
Bold Therapeutics announced that it will present research supporting the use of BOLD-100 at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.
Bold Therapeutics is excited to announce second place in the Innovatorâ€™s Pitch Challenge at the Digital Redefining Early-Stage Investments Conference.
Bold Therapeutics successfully completed Phase 1b of its oncology trial of BOLD-100 combined with FOLFOX in the treatment of advanced gastrointestinal cancers.
Bold Therapeutics announces an extension of the option agreement with Hana Pharm for development and commercialization rights to BOLD-100 in South Korea.
Bold Therapeutics has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in an in vivo model of colorectal cancer.
Bold Therapeutics announces the addition of U.S. Sites for its phase 1b / 2a trial of BOLD-100 in the treatment of advanced GI cancers.
Bold Therapeutics is pleased to be collaborating with Dr. Stephen Barr at Western University to study BOLD-100 in the COVID-19 variants of concern.
Bold Therapeutics announces it is receiving additional funding of up to CAD$965,000 from NRC IRAP to support the development of BOLD-100 as a novel antiviral.
Bold Therapeutics announces that the U.S. Food & Drug Administration has granted BOLD-100 an Orphan Drug Designation in the treatment of gastric cancer.
Bold Therapeutics announces that new research completed by collaborators shows BOLD-100 consistently reduced viral concentrations in COVID-19 variants.
Dr. Van Schaeybroeck will present research supporting BOLD-100 as a potential anti-resistance therapy for BRAF-mutant colorectal cancer at AACR annual meeting.
Bold Therapeutics announces that it is one of four companies selected to receive funding from the National Research Council of Canada for its COVID-19 research.
Bold Therapeutics collaborators at University of Vienna published a study detailing the binding partners and mechanism of action of BOLD-100.
Bold Therapeutics BOLD-100 program was one of only four COVID-19 therapeutics programs selected by the National Research Council for development support.
Bold Therapeutics announced that the first patient for the company’s Phase 1b clinical trial has been enrolled at the Cross Cancer Institute.
Georgetown University has recently published a new manuscript showing that Bold Therapeutics’ BOLD-100 has anti-cancer potential in breast cancer.
Bold Therapeutics recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.
Bold Therapeutics has in vitro data showing that its lead clinical-stage therapeutic, BOLD-100, successfully inhibits live SARS-CoV-2 (COVID-19).
Bold Therapeutics is excited to expand its COVID-19 consortium to include four additional collaborators from prominent institutions in Canada and the U.K.